Device Trial Radar · NCT01600443
Comparison of Microtrauma in Urethra After Usage of Different Catheters
Last checked: Nov 19, 2026Latest source record: Feb 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
Apr 2012
Primary completion
May 2012
Study completion May 2012
Sponsor
- Lead sponsor
- Wellspect HealthCareNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 17, 2012
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is undertaken to investigate if the urethral microtrauma, caused by intermittent catheterization, differs between three hydrophilic catheters for intermittent catheterization, LoFric; SpeediCath (SC) and SpeediCath Compact Male (SCCM). The study is a prospective, randomised, cross-over, single-centre study. Each subject will be randomized to use three different catheter types. Three catheterizations will be performed with each catheter type during one day, with at least two hours between each catheterization. The washout period between catheter switch will be at least one week. The primary objective is to evaluate urethral microtrauma for three hydrophilic catheters with regards to hematuria after intermittent catheterization. The secondary objectives are to evaluate urethral microtrauma for three hydrophilic catheters with regards to pyuria and subjective evaluation after intermittent catheterization. The safety of the three catheters will be evaluated in terms of adverse advents, non-serious and serious, rated for causality. The hypothesis that level of hematuria is equal after using different catheters will be tested using Wilcoxon signed rank test. The hypothesis will be rejected if the p-value is less than 5%.
Conditions
- Hematuria
Interventions
LoFricDevice
Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
SpeediCathDevice
Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
SpeediCath Compact MaleDevice
Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HematuriaTime frame: Approximately 2 hours after last catheterization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Unit, R&D Centre Skåne, Skåne University Hospital
Lund, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.